ABSTRACT
La medicina preventiva clínica nos provee de los fundamentos para realizar un chequeo médico individual en forma sistemática y profesional. Las recomendaciones de la USPSTF son un referente a tener en cuenta porque, están construídas sobre evidencias, pero deben ser adaptadas a la epidemiología y a la cultura de donde proviene el consultante. Junto con las alteraciones biológicas (biomédicas), deben ser considerados los determinantes psico-sociales dentro de los factores de riesgo, ya que pueden ser tanto o más importante para la salud de las personas, que aquellos biológicos
Preventive medicine provide a unique perspective useful, to get effective and professional clinical screening. USPSTF provide important evidence based recommendations to be considered in clinical practice; but it should be adapted according local epidemiological conditions. The psychosocial perspective should be considered together with the biomedical approach in order to improve the screening effectiveness
Subject(s)
Humans , Preventive Medicine , Epidemiology , Neoplasms/prevention & control , Primary Prevention , Chile , Mass Screening , Multiphasic Screening , Diagnostic Tests, Routine , Early Detection of Cancer , Secondary Prevention , Tertiary Prevention , Neoplasms/epidemiologyABSTRACT
Five years ago Chile implemented a Health Care Reform to reduce the great inequalities in health care provision that affects the low- income, high-risk segment of its population. A universal care plan ("AUGE") was designed to make medical coverage available to all Chilean citizens suffering from one of a specifed, growing list of diseases (66 at present time). The diseases are prioritized by the Ministry of Health and its inclusion in the plan is revised periodically by an Advisory Committee according to four cardinal criteria: burden of disease, effectiveness of treatment, specific capacity of the health system and financial costs. The plan is funded by the state and enforced by law through a set of four specific guarantees: access, opportunity, quality and financial protection. This paper reviews the origin and development of the reform, the benefits and drawbacks of the application of the specific guarantees and the perception of the public regarding its strengths and weaknesses.
Subject(s)
Humans , Health Care Reform/organization & administration , Health Services Accessibility , Chile , Health Care Reform/standards , Public Opinion , Universal Health InsuranceABSTRACT
Background: Chile has one of the highest prevalence rate of smoking in the world. Brief counseling interventions for smoking cessation at the primary health care level are effective. Compliance with counseling intervention is strongly associated with beliefs and attitudes of the primary health care team that deliver it. The effectiveness of these interventions improve if they are applied to smoking populations with higher motivation of change and high self-efficacy for quitting. Aim: To study the smoking profile of a group of smoking women in Santiago and to identify beliefs and attitudes of the primary health care team members to implement smoking cessation interventions. Material and Methods: A cross-sectional design that included 306 women smokers attending two primary health care clinics in Santiago. Perceptions, beliefs and attitudes of 34 primary care team members from three clinics in Santiago were explored using a qualitative methodology. Results: The study identified a subgroup of 18% of women highly motivated to quit (decisional stage of change) and a 58% with a high self-efficacy. Beliefs and attitudes of staff at the clinics were characterized by invisibility, ambivalence and fatalism regarding the effectiveness of smoking cessation interventions. Conclusions: There is a subgroup of smoking women with a high probability of quitting if they receive an appropriate counseling. Developing a systematic approach for smoking cessation intervention at the primary care setting in Chile should consider the invisibility, ambivalence and fatalism of primary health care team members towards this topic.
Subject(s)
Adolescent , Adult , Female , Humans , Middle Aged , Attitude of Health Personnel , Health Knowledge, Attitudes, Practice , Primary Health Care , Smoking Cessation , Cross-Sectional Studies , Educational Status , Focus Groups , Income , Motivation , Patient Acceptance of Health Care , Qualitative Research , Self EfficacyABSTRACT
Background: Atenolol is one of the most widely used beta blockers clinically, and has often been used as a reference drug in randomized controlled trials of hypertension. However, questions have been raised about atenolol as the best reference drug for comparisons with other antihypertensives. Thus, our aim was to systematically review the effect of atenolol on cardiovascular morbidity and mortality in hypertensive patients. Methods: Reports were identified through searches of The Cochrane Library, MEDLINE, relevant textbooks, and by personal communication with established researchers in hypertension. Randomized controlled trials that assessed the effect of atenolol on cardiovascular morbidity or mortality in patients with primary hypertension were included. Findings: We identified four studies that compared atenolol with placebo or no treatment, and five that compared atenolol with other antihypertensive drugs. Despite major differences in blood pressure lowering, there were no outcome differences between atenolol and placebo in the four studies, comprising 6,825 patients, who were followed up for a mean of 4.6 years on all-cause mortality (relative risk 1.01 [95% CI 0.89-1.15]), cardiovascular mortality (0.99[0.83-1.18]), or myocardial infarction (0.99 [0.83-1.19]). The risk of stroke, however, tended to be lower in the atenolol than in the placebo group (0.85 [0.72-1.01]). When atenolol was compared with other antihypertensives, there were no major differences in blood pressure lowering between the treatment arms. Our meta-analysis showed a significantly higher mortality (1.13[1.02-1.25]) with atenolol treatment than with other active treatment, in the five studies comprising 17,671 patients who were followed up for a mean of 4.6 years. Moreover, cardiovascular mortality also tended to be higher with atenolol treatment than with other antihypertensive treatment. Stroke was also more frequent with atenolol treatment. Interpretation: Our results cast doubts ...
Subject(s)
Humans , Adrenergic beta-Antagonists/therapeutic use , Antihypertensive Agents/therapeutic use , Atenolol/therapeutic use , Evidence-Based Medicine , Hypertension/drug therapy , Adrenergic beta-Antagonists/adverse effects , Antihypertensive Agents/adverse effects , Atenolol/adverse effects , Randomized Controlled Trials as Topic/standardsABSTRACT
Background: High density lipoprotein (HDL) cholesterol is inversely associated to atherosclerotic cardiovascular risk. Disturbances in HDL cholesterol plasma leves are frecuent in the Chilean population, however the pathophysiological mechanisms are unknown. Aim: To evaluate the mechanisms involved in the hypo and hyper alfalipoproteinemias in Chilean subjects. Materials and Methods: Twenty three subjects with hyperalphalipoproteinemia and 12 with hypoalphalipoproteinemia, paired with control subjects (col-HDL between 35 and 55 mg/dl) were studied. We measured plasma lipids, subfractions and sizing of HDL particles and enzymatic activity of cholesteryl ester transfer protein (CETP), lecithin: cholesterol acyltransferase (LCAT), lipoprotein lipase (LPL) and hepatic lipase (LH). Results: Subjects with hyperalphalipoproteinemia showed significantly higher levels of total HDL-cholesterol (70±2 vs 44±1 mg/dl), HDL 2 (30±3 vs 5±1 mg/dl), Apo A I (175±3 vs 146±4 mg/dl), lower HL activity (23,7±0,8 vs 32,4±1,8 mmol/h/l) and HDL particles of greater size, compared to their controls. Subjects with hypoalphalipoproteinemia, showed significantly lower levels of total HDL-cholesterol (26±1 vs 48±2 mg/dl), HDL 3 (21±1 vs 40±2 mg/dl), Apo A I (107±5 vs 145±7 mg/dl), lower LCAT activity (18,6±1,9 vs 26,2±1,6 nmol/h/ml) and smaller HDL particles, compared to their controls. Conclusion: Changes in hepatic lipase and lecithin cholesterol acyltransferase activities may explain the hyper and hypo alphalipoproteinemia respectively, in Chilean subjects.
Subject(s)
Humans , Male , Adult , Female , Hyperlipoproteinemias , Hypolipoproteinemias , Cholesterol, HDL , Cholesterol, LDL , Chile/epidemiology , Lipoproteins , Lipoproteins, HDL , Lipoproteins, LDLABSTRACT
Background: Half of hypertensive patients with low plasma renin activity have a primary hyperaldosteronism. Among the remaining half, 11ß-hydroxysteroid dehydrogenase type 2 (11ßHSD2) deficiency plays an important role. This enzyme catalyzes the conversion of cortisol to cortisone, avoiding the interaction of cortisol with the mineralocorticoid receptor. If the enzyme fails, cortisol will stimulate sodium and water reabsorption and increase blood pressure. Aim: To determine biochemical alterations, suggestive of 11ßHSD2 deficiency, in low-renin hypertensive patients. Patients and Methods: Twenty eight hypertensive patients with a plasma renin activity of less than 0.5 ng/ml/h and with a plasma aldosterone of less than 5 ng/dl were studied. Twenty eight normotensive patients were studied as controls. Serum cortisol (RIA), cortisone (ELISA) and the serum cortisol/cortisone ratio were determined in all of them, between 9 and 10 AM. Measurements were confirmed by high pressure liquid chromatography. The serum cortisol/cortisone ratio was considered abnormal when its Ln (cortisol/cortisone) value was over 2 standard deviations of the mean. Results: Serum cortisol was higher in hypertensive subjects than in controls (11.1ñ3.3 and 9.2ñ2.8 µg/dl, respectively; p <0.05). No differences were observed in serum cortisone (3.4ñ1.3 and 3.7ñ1.2 µg/dl, respectively). Four hypertensive subjects had an abnormally high Ln (cortisol/cortisone) value (1.86; 1.73; 2.07 and 2.01, considering a normal value of less than 1.61). Conclusions: Four of 28 hypertensive subjects with low plasma renin activity and aldosterone had biochemical alterations suggestive of 11ßHSD2 deficiency